Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 28, 2025 08:00 ET | Source: Alzamend Neuro, Inc.

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Alzamend to Present at 2025 Military Health System Research Symposium; Differences in Lithium Brain-to-Plasma Exposure Between AL001 and Lithium Carbonate
April 03, 2025 08:30 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)

THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted...
January 29, 2025 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on...
April 29, 2024 07:59 ET | Source: Pasithea

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Pasithea Therapeutics' PAS-004 abstract accepted for ASCO poster presentation: novel MEK inhibitor shows promise for NF1 and cancer therapy.
April 08, 2024 08:35 ET | Source: GRI Bio, Inc.

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
January 09, 2024 08:00 ET | Source: Palisade Bio, Inc.

Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress

Carlsbad, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...
June 21, 2023 02:01 ET | Source: Arbutus Biopharma Corporation

Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023

Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or...
March 14, 2023 16:05 ET | Source: Arbutus Biopharma Corporation

Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research

Antiviral potency, selectivity and favorable PK support further development of AB-343 as potential ritonavir-free oral treatment for COVID-19 and other human coronaviruses WARMINSTER, Pa., March 14,...
October 31, 2022 16:02 ET | Source: Arbutus Biopharma Corporation

Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022

Conference Call and Webcast to discuss the new data being presented at AASLD scheduled for 8:45 AM ET, Friday, November 4, 2022 WARMINSTER, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma...
June 03, 2022 09:57 ET | Source: Florida Cancer Specialists & Research Institute

Florida Cancer Specialists & Research Institute Presents Clinical Research Results at 2022 ASCO® Annual Meeting

Fort Myers, Florida, June 03, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLS (FCS) physicians are presenting the outcomes of 33 clinical trials, the majority being...